All In Biotech

Drug Trial Radar · NCT05231785

A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD

A Randomized, Double-blind, Placebo-controlled Single Ascending Dose and Open-label Multi-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-APP in Adult Patients With Early-onset Alzheimer's Disease (EOAD)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 4, 2022

Primary completion

Jan 11, 2029

Study completion Jan 11, 2029

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Feb 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with early-onset Alzheimer's Disease (EOAD). Maximum treatment duration for Part A: single dose. Maximum treatment duration for Part B: 12 months.

Conditions

  • Early-Onset Alzheimer Disease

Interventions

  • ALN-APPDrug

    ALN-APP will be administered intrathecally (IT)

  • PlaceboDrug

    Placebo will be administered IT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Frequency of Adverse EventsTime frame: Up to 12 months
  2. Part B: Frequency of Adverse EventsTime frame: Up to 42 months

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    La Jolla, California · Completed

  • Clinical Trial Site

    Indianapolis, Indiana · Recruiting

  • Clinical Trial Site

    Montreal, Canada · Recruiting

  • Clinical Trial Site

    Toronto, Canada · Recruiting

  • Clinical Trial Site

    Amsterdam, Netherlands · Recruiting

  • Clinical Trial Site

    Groningen, Netherlands · Completed

  • Clinical Trial Site

    Huntley Street, United Kingdom · Recruiting

  • Clinical Trial Site

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.